500 patients66,097 observations150 daysLIVE

Patient P-03167

Synthetic patientONX-7 · Day 140 · 45–54 · F · baseline S10Steering view · 3DOpen companion preview
Is the drug working?

Immune response 82 at the day-84 endpoint (observed).

Why responding?

Responding: response probability 77%, immune response 74 today; biology is not blocking the drug.

Is a side effect starting?

No side effect starting: immune-related gi adverse events 10, immune-related toxicity 14, no drift from the model.

Still taking it?

3 of 4 scheduled doses in the last 60 days are biologically confirmed (75%); 1 were logged but show no dose signature. Dose signature: resting HR +3 bpm, HRV −8 ms.

last 4 doses · green confirmed · amber logged only · red missed
Plan for this patient
stable, no actionrecommendowner · Companionreview day 147Human Model →
Next action
No action indicated; maintain.
Kept if

Trajectory is stable relative to similar patients; keep the current content.

Daily to-dos in the companion
  • 🍽Keep meals regular; three to four moderate portions spaced through the day
  • 🍽Include a cooked vegetable portion with each main meal
  • Log the daily check-in; one line is enough
  • A 15-minute walk after lunch
  • 💊Take the scheduled dose as agreed with your care team
  • 💊No additional supplements this week
Adherence
96% stable

Adherence is not the problem.

Changes the plan if

sleep quality falling under 35 while GI rises

LLIFE OS insight
grounded · add an LLM key for prose

P-03167 is on day 140 of ONX-7 (SR, baseline S10): response declining, tolerance favorable, GI favorable. Over 14 days response moved -6 and GI -2; discontinuation risk is 6%. The state is in the restoration basin, heading towards failing.

Biology sets the gain: Poor metabolizer; butyrate capacity 75/100, diversity 3.0. Pushing it down: Poor metabolizer (-23.9), Enterococcus faecium 4.713% (LPS load) (-23.3), Caffeine (-17.7). Pulling it up: Protein (supports) (+25.7), Butyrate producers intact (+14). From the daily log: protein -6.1 GI next day, caffeine +4.7 GI next day, alcohol +4.3 GI next day, lactose +4.2 GI next day.

No action has been tried yet.

No action is indicated now; the trajectory is stable relative to similar patients.

Therapy response
Declining
Tolerance
Favorable
GI state
Favorable
Inflammatory state
Favorable
Nutritional resilience
Favorable
Discontinuation risk
6%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events
solid = observed · dashed = predicted · dose (infusion on day 1 of each 14-day cycle)
  1. Day 0 ONX-7 startedBaseline state S10

What changed?

Trajectory is tracking the baseline prediction.

Primary contributors, last 14 days
  • Treatment adherence+7
  • Inflammatory activity-4
  • Nutritional resilience+4
  • GI instability-2
  • Toxicity+2

What helped?

No interventions yet.

    LIFE OS recommendation
    No intervention is indicated right now. The trajectory is stable relative to similar patients. See what worked for similar patients.

    Daily trackers

    Asset settings

    The trackers this program marks as important, last 14 days vs the 14 before.

    Energy level
    Daily log
    6.8/10
    worsening · -0.3 vs previous 14 d
    Stress level
    Daily log
    4/10
    worsening · +0.4 vs previous 14 d
    Pessimism score
    Daily log
    2.4/10
    worsening · +0.5 vs previous 14 d
    Sleep quality
    Wearable
    45.1/100
    worsening · -2.3 vs previous 14 d
    Libido
    Daily log
    4.8/10
    stable · -0.1 vs previous 14 d
    HRV
    Wearable
    53.7 ms
    stable · +0.3 vs previous 14 d
    Toxicity
    Blood
    14/100
    worsening · +1.4 vs previous 14 d
    This trajectory is decaying — what would help, what would not
    Steering view →

    Heading towards failing · 90 from the failing basin, 9 from restoration.

    Would help
    • No untried action with strong evidence. Compose one from primitives.
    • More protein
      GI -6.1 next day on high-intake days · n 24
    Would not help
    • Keep caffeine low
      GI +4.7 next day on high-intake days · n 15
    • Keep alcohol low
      GI +4.3 next day on high-intake days · n 21
    • Keep lactose low
      GI +4.2 next day on high-intake days · n 18
    State influencers · digestive

    Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.

    • Protein
      -6.1supporter · 95%
    • Caffeine
      +4.7detractor · 95%
    • Alcohol
      +4.3detractor · 95%
    • Lactose
      +4.2detractor · 95%
    • Histamine load
      -1.3no signal · 32%
    • Dietary fat load
      +0.8no signal · 17%

    DeepGene damage signature

    The metagenomic + host-DNA read-out that initializes this patient's biology and, on retest, measures whether the steering worked.

    Damage score · retest day 90
    29/100
    vs baseline (day 0)
    +13
    1 improved · 6 worsened
    synthetic signature · consistent with this patient's biology
    • 3 opportunists above range: Klebsiella pneumoniae, Enterococcus faecium, Streptococcus gallolyticus
    • 1 keystone species absent
    • 5 resistance genes
    Pathogens / opportunists3/5
    from 2
    Keystone species1/8
    Diversity0/2
    Metabolic modules0/4
    Vitamin synthesis1/7
    Oral translocation1/1
    from 0
    Host DNA0/1
    Tissue recycling0/1
    Central mechanisms0/2
    Virulence factors1/1
    Antibiotic resistance genes5/5
    from 2
    Genetic predisposition2/2
    Opportunists above range
    Enterococcus faecium 4.713% AR
    Klebsiella pneumoniae 2.828% AR
    Streptococcus gallolyticus 0.943% AR
    Keystone species absent
    Akkermansia muciniphila
    Capacity
    Shannon 3.04 · butyrate 770 CPM · SCFA 1222
    1 vitamins below
    Host & mechanisms
    tissue recycling 27/100
    oral translocation 2.17% AR
    5 resistance genes · 1 virulence factors

    Biological layers

    Which pathways look influenced, and by which layer of this person's biology.

    Pathways under pressure
    • Drug metabolism and exposure 40
      • DNACYP2D6 poor metabolizer → higher exposure
    • Autonomic recovery 40
      • Wearable3,676 steps/day
      • WearableShort sleep window
    • Mucosal barrier integrity 30
      • MicrobiomeAkkermansia low → thinner mucus layer
    • Inflammatory signalling 20
      • MicrobiomeBacteroides fragilis expansion
    DNA
    Fictional pharmacogenomic panel
    • CYP2D6 Poor metabolizer
      Higher exposure at standard dose
    • MTHFR C677T
      Reduced folate turnover
    Microbiome
    Shannon diversity 3 · butyrate capacity 75/100
    • Akkermansia muciniphilaLow
    • Faecalibacterium prausnitziiNormal
    • Bacteroides fragilisHigh
    • Bifidobacterium longumNormal
    • EnterobacteriaceaeHigh
    Wearable, last 14 days
    daily evolution fed into the runtime
    HRV
    54 ms
    Sleep
    6.4 h
    Steps
    3,420
    Resting HR
    65 bpm
    Daily log: GI score 10, nutritional resilience 69, adherence 96.

    What this patient sees in NostraAI

    The content that steers the trajectory: what to eat, what to do, what to take.

    Open companion preview
    What to eat
    • Keep meals regular; three to four moderate portions spaced through the day
    • Include a cooked vegetable portion with each main meal
    • Keep fibre steady; no new sources this week
    • Avoid known triggers for now: fried or oily food, dairy, alcohol
    What to do
    • Log the daily check-in; one line is enough
    • A 15-minute walk after lunch
    • Protect a 7.5-hour sleep window; screens off 30 minutes before
    • Keep hydration steady: small amounts through the day rather than large volumes at once
    What to take
    • Take the scheduled dose as agreed with your care team
    • No additional supplements this week
    • Fictional demo item: continue vitamin D as before

    284 biologically similar trajectories

    Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

    PatientSimilarityBaselineInterventionOutcomeResponse today
    P-0308538%S2095
    P-0313439%S0194
    P-0343337%S19CR-01improved94
    P-0307136%S0892
    P-0339441%S2092
    P-0316536%S2092
    P-0318336%S1891
    P-0305142%S1091
    P-0340241%S1891
    P-0326738%S0391
    P-0326837%S1791
    P-0346136%S18ME-01improved91